🚀 VC round data is live in beta, check it out!
Ab&B Bio-Tech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ab&B Bio-Tech and similar public comparables like Hisamitsu Pharmaceutical, Liquidia, SK Bioscience, China Res Double-Crane and more.
Ab&B Bio-Tech Overview
About Ab&B Bio-Tech
Ab&B Bio-Tech Co Ltd JS is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. Its pipeline included two Core Products, the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with 11 other vaccine candidates.
Founded
2015
HQ
Employees
580
Website
Sectors
Financials (FY)
EV
$3B
Ab&B Bio-Tech Financials
Ab&B Bio-Tech reported last fiscal year revenue of $38M and negative EBITDA of ($26M).
In the same fiscal year, Ab&B Bio-Tech generated $22M in gross profit, ($26M) in EBITDA losses, and had net loss of ($38M).
Ab&B Bio-Tech P&L
In the most recent fiscal year, Ab&B Bio-Tech reported revenue of $38M and EBITDA of ($26M).
Ab&B Bio-Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $38M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $22M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 58% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($26M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (70%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (88%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($38M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (100%) | XXX | XXX | XXX |
| Net Debt | — | — | $98M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ab&B Bio-Tech Stock Performance
Ab&B Bio-Tech has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Ab&B Bio-Tech's stock price is $6.82.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $-0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAb&B Bio-Tech Valuation Multiples
Ab&B Bio-Tech trades at 74.4x EV/Revenue multiple, and (106.2x) EV/EBITDA.
Ab&B Bio-Tech Financial Valuation Multiples
As of March 7, 2026, Ab&B Bio-Tech has market cap of $3B and EV of $3B.
Equity research analysts estimate Ab&B Bio-Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ab&B Bio-Tech has a P/E ratio of (71.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 74.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (106.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (84.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 127.5x | XXX | XXX | XXX |
| P/E | — | XXX | (71.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (48.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ab&B Bio-Tech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ab&B Bio-Tech Margins & Growth Rates
Ab&B Bio-Tech's revenue in the last fiscal year grew by 398%.
Ab&B Bio-Tech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 398% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (70%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (51%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 44% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 79% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 147% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ab&B Bio-Tech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hisamitsu Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Liquidia | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| China Res Double-Crane | XXX | XXX | XXX | XXX | XXX | XXX |
| Travere Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ab&B Bio-Tech M&A Activity
Ab&B Bio-Tech acquired XXX companies to date.
Last acquisition by Ab&B Bio-Tech was on XXXXXXXX, XXXXX. Ab&B Bio-Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ab&B Bio-Tech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAb&B Bio-Tech Investment Activity
Ab&B Bio-Tech invested in XXX companies to date.
Ab&B Bio-Tech made its latest investment on XXXXXXXX, XXXXX. Ab&B Bio-Tech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ab&B Bio-Tech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ab&B Bio-Tech
| When was Ab&B Bio-Tech founded? | Ab&B Bio-Tech was founded in 2015. |
| Where is Ab&B Bio-Tech headquartered? | Ab&B Bio-Tech is headquartered in China. |
| How many employees does Ab&B Bio-Tech have? | As of today, Ab&B Bio-Tech has over 580 employees. |
| Is Ab&B Bio-Tech publicly listed? | Yes, Ab&B Bio-Tech is a public company listed on HKEX. |
| What is the stock symbol of Ab&B Bio-Tech? | Ab&B Bio-Tech trades under 02627 ticker. |
| When did Ab&B Bio-Tech go public? | Ab&B Bio-Tech went public in 2025. |
| Who are competitors of Ab&B Bio-Tech? | Ab&B Bio-Tech main competitors are Hisamitsu Pharmaceutical, Liquidia, SK Bioscience, China Res Double-Crane. |
| What is the current market cap of Ab&B Bio-Tech? | Ab&B Bio-Tech's current market cap is $3B. |
| What is the current revenue of Ab&B Bio-Tech? | Ab&B Bio-Tech's last fiscal year revenue is $38M. |
| What is the current EV/Revenue multiple of Ab&B Bio-Tech? | Current revenue multiple of Ab&B Bio-Tech is 74.4x. |
| Is Ab&B Bio-Tech profitable? | No, Ab&B Bio-Tech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.